Liquidia (NASDAQ:LQDA) Insider Jason Adair Sells 688 Shares

Liquidia Corporation (NASDAQ:LQDA) insider Jason Adair sold 688 shares of the company’s stock in a transaction dated Monday, April 27th. The shares were sold at an average price of $41.65, for a total transaction of $28,655.20. Following the transaction, the insider directly owned 214,738 shares of the company’s stock, valued at $8,943,837.70. This represents a 0.32% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Jason Adair also recently made the following trade(s):

• On Monday, April 13th, Jason Adair sold 7,301 shares of Liquidia stock. The shares were sold at an average price of $38.37, for a total transaction of $280,139.37.

Liquidia Stock Performance

Shares of LQDA traded up $0.50 during trading hours on Wednesday, reaching $38.15. 559,561 shares of the company traded hands, compared to its average volume of 1,676,301. The stock’s fifty day moving average is $36.32 and its 200 day moving average is $34.10. The stock has a market cap of $3.39 billion, a P/E ratio of -45.96 and a beta of 0.45. The company has a debt-to-equity ratio of 2.97, a quick ratio of 1.84 and a current ratio of 2.01. Liquidia Corporation has a 1-year low of $11.85 and a 1-year high of $46.67.

Liquidia (NASDAQ:LQDA) last announced its quarterly earnings data on Thursday, March 5th. The company reported $0.15 EPS for the quarter, beating analysts’ consensus estimates of $0.08 by $0.07. The business had revenue of $92.02 million during the quarter, compared to analyst estimates of $87.49 million. Liquidia had a negative net margin of 43.53% and a negative return on equity of 209.33%. The business’s quarterly revenue was up 3072.4% compared to the same quarter last year. Equities research analysts anticipate that Liquidia Corporation will post 1.75 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have recently commented on the stock. Raymond James Financial reaffirmed a “strong-buy” rating on shares of Liquidia in a research report on Thursday, March 5th. HC Wainwright increased their price target on shares of Liquidia from $50.00 to $55.00 and gave the stock a “buy” rating in a research report on Friday, March 6th. Wells Fargo & Company increased their price target on shares of Liquidia from $44.00 to $51.00 and gave the stock an “overweight” rating in a research report on Monday, March 23rd. Oppenheimer increased their price target on shares of Liquidia from $16.00 to $19.00 and gave the stock an “underperform” rating in a research report on Thursday, March 12th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Liquidia in a research report on Tuesday, April 21st. Two investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $43.44.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in LQDA. Northwestern Mutual Wealth Management Co. acquired a new position in Liquidia in the fourth quarter worth about $25,000. NewEdge Advisors LLC acquired a new position in Liquidia in the second quarter worth about $25,000. Skandinaviska Enskilda Banken AB publ acquired a new position in Liquidia in the third quarter worth about $30,000. FNY Investment Advisers LLC bought a new stake in Liquidia during the third quarter worth about $34,000. Finally, Covestor Ltd increased its holdings in shares of Liquidia by 41.9% during the fourth quarter. Covestor Ltd now owns 1,216 shares of the company’s stock worth $42,000 after buying an additional 359 shares in the last quarter. Institutional investors and hedge funds own 64.54% of the company’s stock.

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).